Carol Prives, innocent victim of Susana Gonzalez’ data manipulations?

Carol Prives, innocent victim of Susana Gonzalez’ data manipulations?

Recent news brought us yet another retraction of the Spanish zombie scientist Susana Gonzalez, formerly famous for her impactful ERC-funded research into stem cells and ageing. It is her fifth retraction (others here), and meanwhile Gonzalez is not even a zombie scientist anymore. She has no research group in her new Madrid institute, noone in Spain wants to work in the same building with her, in fact though she is still formally employed with the Spanish Consejo Superior de Investigaciones Científicas (CSIC), it seems she stopped coming to work long ago, being on an endless sick leave. Even the European Research Council (ERC), usually most accommodating with research misconduct of their elite grant recipients, didn’t know what to do with Gonzalez suspended €2Mn grant and eventually terminated it.

The recent Gonzalez retraction at the  Molecular and Cellular Biology (MCB) is interesting in two aspects. First, Retraction Watch previously chastised the journal in a headline for allegedly refusing to investigate evidence of data manipulations in papers older than 6 years (read here). No reference is made to that “smear” accusation in the current Retraction Watch article on Gonzalez retraction.  But the second aspect is really much more intriguing. The retracted MCB paper, from Gonzalez period as postdoc at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York, was coauthored by the US researcher Carol Prives, professor at the Columbia University in New York, and specialist for the cell cycle control protein p53: Continue reading “Carol Prives, innocent victim of Susana Gonzalez’ data manipulations?”

The PubPeer Stars of Weizmann Institute

The PubPeer Stars of Weizmann Institute

Journals generally avoid acting on data manipulation, unless forced to by investigations from universities and research institutions. The Lancet‘s current stance on Macchiarini (and previously Wakefield) affair is probably the most dangerous example. Practically at every single research integrity conference (which are usually organised by major publishers like Elsevier), publishing executives preach that journals should never be asked to deal with data manipulations in papers they publish,  but only respond to the final results of institutional investigations.

Actually, even there journals prefer not to retract as requested, as Science did in the case of Olivier Voinnet. On the other hand, some publishers are ready to forgive all misconduct when a unrepentant cheater offers them a new hot paper. Nature Publishing group, EMBO Press and even the publisher lobby group COPE recently protested against journals’ cheater blacklists, in connection with the data-faking plant researcher Patrice Dunoyer, a past Voinnet associate (his story here). And some journals even openly take the side of cheater scientists, while attacking PubPeer whistleblowers, as F1000 Research seemingly did, see tweet below.

Scholarly journals mostly act like grocery shops, which despite better knowledge refuse to remove contaminated foods off the shelves until manufacturer’s official recall, regardless of how many glass shards were found inside. It therefore lies in the hands of research institutions when fraud and cheating continue unabated, while research community is fooled and robbed, left alone with futile attempts to reproduce dishonest papers full of secret data manipulations. Yet this is exactly what Weizmann Institute of Science in Israel is good at:

The Art of Not Investigating

The following article lists Weizmann scientists with some serious evidence on PubPeer against the trustworthiness of their research. Before this elite institution from Rehovot, that most famous biomedical research centre in Israel, dismisses my article as anti-Semitic slander of an obscure German Nazi blogger, they should first try it with declaring me an assimilation-corrupted, self-hating diaspora Jew. Continue reading “The PubPeer Stars of Weizmann Institute”

Anil Sood and other questionable stars of MD Anderson

Anil Sood and other questionable stars of MD Anderson

The MD Anderson Cancer Center, part of the University of Texas and located in Houston, is a giant hub of huge cancer research money, even for US standards. They also do a lot of science there, which only purpose seems to be publishing in big journals in order to generate even more money. If there is any genuine interest to help cancer patients with actual research: this stands in a stark contrast with MD Anderson’s evident attitude to research reproducibility and data integrity. A number of their star researchers who published in most respectable journals papers, had their data flagged on the whistleblowing platform PubPeer as highly problematic. Yet MD Anderson apparently cannot care less. Their star cancer researcher and businessman Raghu Kalluri was never investigated for many problems in his publications, either in those with or those without his misconduct-tainted Portuguese co-author and ex-MD Anderson employee Sonia Melo. When nobody ever investigates your research practices (e.g., because your research institution is blinded by the investor money you brought in), you will per definition never be found guilty of any misconduct. This is probably exactly why the elite journal Nature recently accepted a new paper from the Kalluri lab (Kamerkar et al 2017), on the same topic of exosomes as cancer biomarkers as his irreproducible earlier masterpiece with Melo (Melo et al, Nature 2015). The new Nature paper even again features the same disgraced co-author, who lost a Nature Genetics paper (Melo et al, 2009) and her EMBO Young Investigator funding due to data manipulation.

There is more evidence for research misconduct at MD Anderson. Continue reading “Anil Sood and other questionable stars of MD Anderson”

Melo and Kalluri defend discredited Nature paper with preprint, where they admit data “adjustments”

Melo and Kalluri defend discredited Nature paper with preprint, where they admit data “adjustments”

Sonia Melo, the Portuguese cheater scientist and her former US-boss Raghu Kalluri issued some days ago a biorxive preprint, which sole purpose is to defend their discredited Nature paper from 2015. There, they originally claimed to have found a unique biomarker for early pancreatic cancer, a much hailed promise to save lives of many cancer patients. However, soon it was found out that the results were not reproducible, the Nature paper Melo et al, 2015 contained evidence of data manipulation (just like other Melo publications with Kalluri and her PhD boss Manel Esteller). The antibody, on which the central evidence for the allegedly unique pancreatic cancer biomarker glypican 1 (GPC1) was based, proved to be delivering staining artefacts; the vendor Thermo Scientific soon discontinued it. Even Kalluri seemingly distanced himself from his results.

Now in their new preprint, Melo and Kalluri claimed to have perfectly reproduced their original 2015 GPC1 results with a new antibody, which however proved to be likely exactly the same as the old one, but sold by a different vendor.  As soon as this became known, the authors issued a new preprint version just two days later, featuring yet another entirely new GPC1 antibody, with an utterly new set of results to complement the 6 day older ones.  However, also these results are most likely useless. The authors namely freely admit in their preprint method description to have intentionally manipulated their flow cytometry (FACS) data to obtain a positive signal specifically where needed. It seems that one full professor and three research group leaders have absolutely no understanding about data integrity in flow cytometry (or maybe even in research in general). Obviously, they simply adjust the FACS settings for each sample in an analytic row any way it pleases them until they see a result they like. As they don’t even hide it, they seem to think this is the proper way to do science. Continue reading “Melo and Kalluri defend discredited Nature paper with preprint, where they admit data “adjustments””

Pfizer announces more retractions for sacked lab head Min-Jean Yin, whistleblower revealed

The pharma giant Pfizer announced to continue investigating the data manipulations committed by their former cancer researcher Min-Jean Yin, retractions of two more publications were requested and yet another paper’s fate is being currently decided. Again it is about studies of pharmacological inhibitors of cancer molecular pathways which Yin’s former lab at the Pfizer California research site has faked. These two retraction requests come is addition to 5 Yin retractions which Pfizer already announced on my site in October 2016 and which meanwhile happened. The PubPeer-listed evidence was first presented on my site in May 2016. Back then, the reader of my site, who posted that evidence of duplicated western blots on PubPeer and alerted me to it, preferred to remain unnamed. Now however, she agreed to be named: it was the microbiologist, image integrity specialist and host of the successful public outreach blog Microbiome Digest, Elisabeth Bik. She now forwarded to me this message: Continue reading “Pfizer announces more retractions for sacked lab head Min-Jean Yin, whistleblower revealed”

The vexatious life-saving question of cadaveric tracheas

The vexatious life-saving question of cadaveric tracheas

As we learned it from the Swedish documentary „Experimenten“, the scandal trachea surgeon Paolo Macchiarini didn’t much like to operate on sick cancer patients: they died too quickly after receiving a trachea transplant. This is why Macchiarini was said to have moved on to patients outside of any life-threatening conditions, like the Russian car accident victim Yulia Tuulik. She died because of the plastic trachea which Macchiarini implanted into her. Yesim Cetir, young victim of a botched operation, was slightly luckier to survive the plastic trachea, but only because it was removed and because of constant emergency care and multiple organ transplants (she is presently in very grave state). However, it seems that even Macchiarini’s cancer patients could have led a relatively long life, had they not agreed to receive his trachea transplants. And I am not speaking about the lethal plastic ones. In fact, the “biological” grafts made of decellurised dead donor tracheas were not such a great success either, and seem to have brought suffering and have shortened lives instead of prolonging them. The British UCL and its hospital UCLH are preparing their own clinical trial with cadaveric tracheas, while busily covering up their role in the Macchiarini scandal.

Continue reading “The vexatious life-saving question of cadaveric tracheas”

Post-publication peer review of a multimillion-dollar-heavy Nature paper, by Ana Pedro

Post-publication peer review of a multimillion-dollar-heavy Nature paper, by Ana Pedro

The Portuguese cancer researcher Sonia Melo has now achieved the status of a zombie scientist. After an internal investigation which records are kept secret, she was cleared of all suspicions of scientific misconduct and re-installed as group leader at the Instituto de Investigação e Inovação em Saúde (I3S) in Porto (see my report here). This despite an impressive PubPeer record of data integrity concerns, and despite the fact that the European research society EMBO revoked Melo’s Installation Grant funding after having determined problems with her publications. EMBO nevertheless stick to their decision, but Melo’s Portuguese funders like Fundação para a Ciência e a Tecnologia (FCT) apparently see absolutely no need to reconsider their support, certainly not after the I3S whitewashing. Melo previously had to retract a paper (Melo et al, Nature Genetics, 2009) for data manipulations, her other works were however found not problematic by the I3S commission. In two papers in Cancer Cell (Melo et al 2010 and Melo et al 2014), the alleged duplications were apparently proven not to be duplications. As I learned, this was probably because while the top part of the gel images indeed did look suspiciously similar, the lower parts were clearly different. A possibility of digital image splicing was not considered, as it seems. In any case, even if the top bands are indeed the same, it doesn’t really matter. Cell editorial offices made on several occasions perfectly clear that data integrity is not one of their top concerns.

f5krhwn
From Melo et al, Cancer Cell, 2014. Cannot be a duplication, according to I3S. Source: PubPeer

Continue reading “Post-publication peer review of a multimillion-dollar-heavy Nature paper, by Ana Pedro”